MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.ajkd.2007.03.008

Медицинская библиотека · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2007

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum Larry A, Benador Nadine, Goldstein Stuart L, Paredes Ana, Melnick Joel Z, Mattingly Susan, Amdahl Michael, Williams Laura A, Salusky Isidro B

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Secondary hyperparathyroidism is a common complication in children receiving hemodialysis. Active vitamin D is an effective therapy, but its use is often limited by hypercalcemia and increased calcium x phosphorus (Ca x P) product. Paricalcitol, a selective vitamin D receptor activator, causes less sustained hypercalcemia and increase in Ca x P product than calcitriol and has been used effectively in adult hemodialysis patients.

STUDY

DESIGN

Double blind, placebo-controlled.

SETTING &

PARTICIPANTS

Hemodialysis units and pediatric subjects receiving hemodialysis.

INTERVENTION: After a washout period of 2 to 6 weeks, 29 subjects aged 5 to 19 years received either paricalcitol or placebo for up to 12 weeks (0.04 mug/kg if initial intact parathyroid hormone [iPTH] level < 500 pg/mL [ng/L]; 0.08 mug/kg if initial iPTH level > 500 pg/mL [ng/L]). The dose was increased by 0.04 mug/kg every 2 weeks until there was a 30% decrease in iPTH level from baseline or calcium level greater than 11 mg/dL (>2.74 mmol/L) or Ca x P product greater than 75 mg(2)/dL(2) (>6.04 mmol(2)/L(2)).

OUTCOMES & MEASUREMENTS: Two consecutive 30% decreases from baseline in iPTH levels and safety of paricalcitol, including hypercalcemia and increase in Ca x P product.

RESULTS

60% of the paricalcitol group had 2 consecutive 30% decreases from baseline iPTH levels compared with 21% in the placebo group (P = 0.06). The paricalcitol group had a mean decrease in iPTH level of 164 pg/mL (ng/L), whereas the placebo group had a mean increase of 238 pg/mL (ng/L; P = 0.03). There was no difference from baseline to final visit in calcium, phosphorus, or Ca x P product values in either group.

LIMITATIONS: Low power to detect differences in safety between groups and a short-term study.

CONCLUSION

Paricalcitol decreased iPTH levels in children receiving hemodialysis with no significant changes in serum calcium, phosphorus, or Ca x P product values during the course of the study.

Для цитирования: Greenbaum Larry A, Benador Nadine, Goldstein Stuart L, Paredes Ana, Melnick Joel Z, Mattingly Susan, Amdahl Michael, Williams Laura A, Salusky Isidro B. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2007. DOI: 10.1053/j.ajkd.2007.03.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.